More reasons why the method is new and so valuable in my opinion:
The introduction of a novel method for treating unresectable, locally advanced pancreatic tumors represents a groundbreaking advance in oncology.
This method, which received CE certification on March 30, 2020, is unparalleled in its approach and potential impact.
Here's why:
Innovation in Treatment: The technique uses endoscopic intratumoral injection of 32P-labeled microparticles suspended in a carrier solution. This is administered under ultrasound guidance, in addition to systemic chemotherapy. This multi-pronged approach has the potential to greatly enhance the efficacy of treatment.
First of its Kind: This treatment, which combines radioactively labeled microparticles with systemic chemotherapy, is the first of its kind to be approved in the European Economic Area. The unique combination offers a new frontier in the battle against pancreatic cancer.
No Prior OPS Coding: Its revolutionary nature is underlined by the fact that it could not be OPS coded previously, which means that there was no established procedure for this form of treatment. This highlights the truly pioneering nature of the therapy.
Potential for Increased Efficacy: The use of both radioactively labeled particles and systemic chemotherapy could offer a dual mode of attack against tumors, which may result in greater treatment efficacy.
Filling a Gap in Treatment Options: Pancreatic tumors that are locally advanced and unresectable have limited treatment options. This novel technique could offer a lifeline to patients who have exhausted other avenues.
Certification: The CE certification ensures that the method meets high safety and efficacy standards, providing assurance to both healthcare providers and patients.
Global Relevance: While it's groundbreaking in the context of Germany and the European Economic Area, the method has the potential for global adoption, setting a new standard in pancreatic cancer treatment.
In summary, this revolutionary treatment stands to not only significantly advance pancreatic cancer therapy but also offers hope to countless patients, potentially setting a new global benchmark in cancer care.Please note, above is Personal opinion, using public available sources on Google and Nuklearmedizin website, conduct your own research and ask your financial adviser.
- Forums
- ASX - By Stock
- Ann: Change of principal place of business
OSL
oncosil medical ltd
Add to My Watchlist
1.48%
!
$1.03

More reasons why the method is new and so valuable in my...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.03 |
Change
0.015(1.48%) |
Mkt cap ! $14.65M |
Open | High | Low | Value | Volume |
$1.05 | $1.05 | 95.0¢ | $109.7K | 112.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 23906 | $1.00 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.05 | 2292 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 23906 | 1.000 |
1 | 2875 | 0.980 |
1 | 1000 | 0.970 |
1 | 1000 | 0.960 |
3 | 2600 | 0.950 |
Price($) | Vol. | No. |
---|---|---|
1.045 | 2292 | 2 |
1.050 | 25048 | 2 |
1.075 | 1879 | 1 |
1.090 | 2875 | 2 |
1.180 | 2500 | 1 |
Last trade - 15.57pm 19/06/2025 (20 minute delay) ? |
Featured News
OSL (ASX) Chart |
The Watchlist
RML
RESOLUTION MINERALS LTD
Craig Lindsay, In-Country CEO
Craig Lindsay
In-Country CEO
SPONSORED BY The Market Online